rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    FATE
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Fate Therapeutics Presents New FT819 Data at ACR Convergence 2026 Highlighting Meaningful Clinical Responses in Lupus Without the Use of Conditioning Chemotherapy
      Nov 10Yahoo FinanceFATE
      Fate Therapeutics: Q3 Earnings Snapshot
      Nov 5Yahoo FinanceFATE
      Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
      Nov 5Yahoo FinanceFATE
      Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
      Nov 3Yahoo FinanceFATE
      Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026

      Active LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with approximately 50% mean reduction in proteinuria Encouraging safety profile with no dose-limiting toxicities, high-grade CRS, ICANS, GvHD or IEC-HS in autoimmune patients treated with a single dose of FT819; low incidences of infection and cytopenia were also observed Clinical data reinforces the patie

      Oct 26Yahoo FinanceFATE
      Fate Therapeutics appoints Jamie Harrell to lead commercial strategy
      Oct 12Investing.comFATE
      Fate Therapeutics appoints Jamie Harrell to lead commercialization
      Oct 12Investing.comFATE
      Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies
      Oct 12Yahoo FinanceFATE
      Analysts Conflicted on These Healthcare Names: Dexcom (DXCM) and Fate Therapeutics (FATE)

      Detailed price information for Dexcom Inc (DXCM-Q) from The Globe and Mail including charting and trades.

      Oct 6The Globe and MailFATE
      Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on October 1, 2026, the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 62,900 shares of the Company’s common stock

      Oct 2Yahoo FinanceFATE
      Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
      Oct 1Yahoo FinanceFATE
      Fate Therapeutics Receives $15 Million Grant for Lupus Treatment Trial

      Fate Therapeutics (FATE) has been awarded a $15 million grant from the California Institute for Rege

      Sep 25Yahoo FinanceFATE
      Fate Therapeutics receives $15m CIRM grant for lupus trial
      Sep 25Investing.comFATE
      Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

      $15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus Nephritis CLIN2 Grant is a highly competitive award from CIRM to fund advancing clinical trials for stem cell and gene therapies that have the potential to provide transformative benefits to patients and the healthcare system SAN DIEGO, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical c

      Sep 25Yahoo FinanceFATE
      Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026

      SAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disease, today announced that four abstracts from its off-the-shelf CAR T-cell programs have been selected for presentation at the American College of Rheumatology (ACR) Convergence 2026, being held November 6-1

      Sep 16Yahoo FinanceFATE
      Fate Therapeutics at Cantor conference: autoimmune CAR-T push advances
      Sep 9Investing.comFATE
      Fate Therapeutics presents FT819 lupus trial data at conference
      Sep 9Investing.comFATE
      Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
      Sep 9Yahoo FinanceFATE
      Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

      SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in a fireside chat at the 2026 Annual Cantor Global Healthcare Conference, being held September 9–12, 2026 in New York, NY. Discussion topics will inclu

      Sep 3Yahoo FinanceFATE
      Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead (NASDAQ:FATE)

      Fate Therapeutics starts Phase 2 RECLAIM-LN trial of FT819 in lupus nephritis, with Phase 1 promise and pipeline updates. Click here to read this analysis.

      Sep 2Seeking AlphaFATE
      Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. | The Motley Fool

      One of J&J's investments stands head-and-shoulders above the rest.

      Aug 31The Motley FoolFATEPTGXJNJ

      This is the newest page. Registered accounts read further back.